Comparative Pharmacology
Head-to-head clinical analysis: QUELICIN versus QUELICIN PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUELICIN versus QUELICIN PRESERVATIVE FREE.
QUELICIN vs QUELICIN PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depolarizing neuromuscular blocker that binds to nicotinic acetylcholine receptors at the motor end-plate, causing persistent depolarization and preventing repolarization, resulting in neuromuscular blockade.
Depolarizing neuromuscular blocker that binds to nicotinic acetylcholine receptors at the motor end-plate, causing initial depolarization followed by sustained membrane depolarization and neuromuscular blockade.
1 mg/kg IV bolus for rapid sequence intubation; maintenance infusion 0.5-1 mg/min IV for prolonged procedures.
1.0-2.0 mg/kg intravenously; 0.3-1.1 mg/kg intramuscularly. For intravenous administration, typical adult dose is 40-100 mg. Repeat doses of 0.04-0.07 mg/kg as needed for maintenance.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 minutes in normal patients; prolonged to 20-40 minutes in patients with pseudocholinesterase deficiency.
2 to 4 minutes (pseudocholinesterase-mediated hydrolysis); prolonged in patients with atypical pseudocholinesterase or hepatic impairment.
Primarily hydrolyzed by plasma pseudocholinesterase; less than 2% excreted unchanged in urine; minimal biliary/fecal elimination.
Primarily hydrolyzed by plasma pseudocholinesterase; less than 2% excreted unchanged in urine; minimal biliary/fecal elimination.
Category C
Category C
Neuromuscular Blocker (Depolarizing)
Neuromuscular Blocker (Depolarizing)